echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > When the bow is opened, the drugs are not collected into the deep water area

    When the bow is opened, the drugs are not collected into the deep water area

    • Last Update: 2019-11-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Wen Jie Liang Jian At the executive meeting of the State Council on November 20, Premier Li Keqiang gave a new instruction on the centralized purchase of drugs, which has caused a heated discussion in the industry recently According to official media reports, Premier Li Keqiang put forward four requirements at the executive meeting of the State Council, namely: First, expand the scope of centralized procurement and use of drugs Priority should be given to the varieties with large price difference between the original research drug and the generic drug, as well as the essential drugs that pass the consistency evaluation of the quality and efficacy of the generic drug, etc into the centralized procurement, so as to promote the substantial reduction of the drug price through the volume procurement We will build a national centralized procurement platform for drugs, and build a unified and open procurement market nationwide based on provinces (districts, cities) Second, ensure the stable supply and quality safety of drugs purchased in a centralized way Establish an emergency reserve, inventory and capacity reporting system for bid winning production enterprises, strengthen the sampling inspection of bid winning drugs, and implement the market clearance system We will build a drug traceability system, take the lead in realizing "one thing, one code" for vaccines and drugs purchased and used centrally by the state by the end of next year, which can be independently inspected by the public Third, formulate and implement national drug administration measures We will promote medical institutions to first use national essential drugs and Medicare listed drugs We will strengthen the management of pharmaceutical affairs in hospitals and investigate and deal with irrational drug use in accordance with the law Establish and improve the regulatory mechanism for the normalization of drug prices On the premise of not increasing the burden of patients as a whole, we will explore the optimization of medical service price in a stable and orderly pilot Fourth, we will push forward the reform of payment methods for medical insurance In principle, the same payment standard shall be applied to the original research drug with the same generic name, the generic drug with the same dosage form and specification, and the generic drug passing the consistency evaluation Explore more efficient ways to pay for drugs In fact, for the process of China's medical reform, the impact of policies accounts for a considerable proportion, so we can also find some clues from the above four requirements for the future development of centralized drug procurement and national medical insurance negotiation and access First of all, it needs to be clear that for the public authority, the reform has not turned around Centralized drug procurement cannot be stopped or changed in the future The reform is also a trial and error process In this medical reform, any party is feeling the stones and crossing the river Officially, enterprises are also Premier Li Keqiang's first requirement is to expand the scope of centralized purchase and use of drug varieties, which is very important because the government has considered that the measures such as centralized purchase bidding conducted at the end of last year are feasible, which are in line with the government's original intention to reduce drug prices, increase medical insurance fees, squeeze out water with high drug prices and meet the public's access to new drugs According to the current situation, these goals have been achieved or are on the way For example, in the first bidding, the price of the original research drug gefitinib is reduced by 76%, which is more than 25% lower than that of the surrounding countries and regions The cost of gefitinib in the treatment of lung cancer was reduced from 2360 yuan to 547 yuan, a 77% decrease, and the economic burden of medical treatment was reduced In addition, the important point of centralized drug purchase is to continue to promote the control of medical insurance fees We can find clues from the 2018 national basic medical insurance development statistical bulletin published by the State Medical Insurance Bureau In the bulletin, in 2018, the total income of the national basic medical insurance fund was 2138.4 billion yuan, an increase of 19.3% over the previous year; the total expenditure of the national basic medical insurance fund was 1782.2 billion yuan, an increase of 23.6% over the previous year, and the total balance of the national basic medical insurance fund was 2344 billion yuan, including the total balance of the basic medical insurance co-ordination fund was 1615.6 billion yuan, and the total balance of the individual account of employee medical insurance was 728.4 billion yuan Compared with the data in 2017, it can be found that the growth rate of both income and expenditure slowed down In 2017, the total income of the national basic medical insurance fund was 1793.2 billion yuan, and the expenditure was 1442.2 billion yuan, up 37% and 33.9% respectively compared with the previous year At the end of the year, the total balance of basic medical insurance co-ordination fund was 1323.4 billion yuan Through calculation, it is found that last year's medical insurance balance was 2.1 trillion yuan, and the balance of medical insurance fund in 2018 did increase significantly compared with that in 2017, and the effect of medical insurance fee control in 2018 was also improved However, from the perspective of expenditure, these balances are only enough to maintain the total expenditure of basic medical insurance fund in the whole country for one year, and the anti risk is not high, so it is necessary to continue the medical insurance fee control Among the four requirements, it is also very important to formulate and implement the national drug administration measures The significance of this point lies in the official intention to consolidate the results of centralized drug procurement bidding through legislative channels The current drug administration can be said to be Jiulong water control, and there are different policies in different regions However, since the centralized purchase of drugs is organized by the National Health Insurance Bureau, it is imperative to formulate a unified drug administration policy in the future From this point of view, it can be seen as one of the means for the National Health Insurance Bureau to further centralize its power (see: new thinking of medical insurance Negotiation: the medical insurance bureau will lose when the pharmaceutical companies go to the medical insurance bureau?) The fourth point is the most important point in my opinion, to promote the reform of medical insurance payment mode On this point, when the state health insurance bureau released the list of 30 pilot cities for DRG payment in May this year, according to the official schedule, DRG payment mechanism will be simulated in 2020 and officially launched in 2021.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.